The company has substantially boosted its development of an novel treatment for cardiac amyloidosis, utilizing Attruby. Preliminary trial data suggests promising benefits for individuals suffering with this debilitating condition. The effort underscores the company’s commitment to addressing unmet medical requirements in a heart field. Attruby: